Skip to main content
SpringerLink
Log in

Familial Factors in Cancer of the Genitourinary Tract

  • Chapter
Familial and Hereditary Tumors

Part of the book series: Recent Results in Cancer Research ((RECENTCANCER,volume 136))

  • 65 Accesses

Abstract

Cancer of the genitourinary tract includes tumors of the kidney, bladder, prostate, and testis; together these neoplasms represent approximately 25% of all malignancies in the male sex. Ovarian tumors have already been described in the chapter on “Hereditary and Familial Ovarian Cancer,” and endometrial carcinoma in the chapter on “Hereditary and Familial Colorectal Cancer,” as part of Lynch syndrome II. Wilms’ tumor — undoubtedly the most interesting tumor of the genitourinary tract, for its genetic implications — has already been considered in the chapter on “Genetic Factors in Solid Tumors of Childhood,” together with other malignancies of childhood.

When the DNA from the human EJ bladder cancer cell line was introduced into mouse 3T3 cells and the cultures observed, foci of transformed mouse cells appeared. No such foci appeared when DNA from a non-malignant source was used. This strongly supported the notion that the bladder cancer DNA contained a dominantly acting cancer gene, which was promptly named as oncogene. (T. D. Gelehrter and F. S. Collins 1990)

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Zaridze DG, Boyle P (1987) Cancer of the prostate: epidemiology and etiology. Br J Urol 59:493–502

    Article  PubMed  CAS  Google Scholar 

  2. Gittes RF (1991) Carcinoma of the prostate. N Engl J Med 324:236–245

    Article  PubMed  CAS  Google Scholar 

  3. Ross RK, Bernstein L, Judd H et al. (1986) Serum testosterone levels in healthy young black and white men. JNCI 76:45–48

    PubMed  CAS  Google Scholar 

  4. Silverberg E, Lebera JA (1989) Cancer Statistics 1989. CA 39:3–21

    Article  PubMed  CAS  Google Scholar 

  5. King H, Bailar JC III (1966) Epidemiology of urinary bladder cancer: a review of selected literature. J Chronic Dis 19:735–772

    Article  PubMed  CAS  Google Scholar 

  6. Wynder EL, Goldsmith R (1977) The epidemiology of bladder cancer: a second look. Cancer 40:1246–1268

    Article  PubMed  CAS  Google Scholar 

  7. Hueper WC, Wiley PH, Wolfe HD (1938) Experimental production of bladder tumors in dogs by administration of beta-naphthylamine. J Industr Hyg Toxicol 20:46–53

    CAS  Google Scholar 

  8. McCredie M, Stewart JH, Ford JM et al. (1983) Phenacetin-containing analgesics and cancer of the bladder or renal pelvis in women. Br J Urol 55:220–225

    Article  PubMed  CAS  Google Scholar 

  9. Raghavan D, Shipley WU, Garnick MB et al. (1990) Biology and management of bladder cancer. N Engl J Med 322:1129–1137

    Article  PubMed  CAS  Google Scholar 

  10. Zanetti R, Crosignani P (1992) Cancer in Italy: incidence data from cancer registries 1983-1987. tiLega Italiana Lotta contro i Tumori, Torino

    Google Scholar 

  11. Devesa SS, Silverman DT, Young LY et al. (1987) Cancer incidence and mortality trends among whites in the United States. JNCI 79:701–770

    PubMed  CAS  Google Scholar 

  12. Doll R, Peto R (1981) The causes of cancer. JNCI 66:1191–1308

    PubMed  CAS  Google Scholar 

  13. Byrne J, Kessler LG, Devesa SS (1992) The prevalence of cancer among adults in USA. Cancer 69:2154–2159

    Article  PubMed  CAS  Google Scholar 

  14. Scott R, Mutchnik DL, Laskowski TZ et al. (1969) Carcinoma of the prostate in elderly men: incidence, growth characteristics and clinical significance. J Urol 101:602–607

    PubMed  Google Scholar 

  15. Pienta KJ, Esper PS (1993) Risk factors for prostate cancer. Ann Intern Med 118:793–803

    PubMed  CAS  Google Scholar 

  16. Stamey TA (1989) Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate. Urol Monogr 10:50–64

    Google Scholar 

  17. Hudson MA, Bahanson RR, Catalona WJ (1989) Clinical use of prostate specific antigen in patients with prostate cancer. J Urol 142:1011–1017

    PubMed  CAS  Google Scholar 

  18. Chodak GW (1989) Screening for prostate cancer: role of ultrasonography. Urol Clin North Am 16:657–661

    PubMed  CAS  Google Scholar 

  19. Lange PH, Brawer MK (1989) Serum prostate-specific antigen: its use in diagnosis and management of prostate cancer. Urology 33[Suppl 6]:13–17

    Article  PubMed  CAS  Google Scholar 

  20. Stamey TA, Yang N, Hay AR et al. (1987) Prostate specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med 317:1916–1920

    Article  Google Scholar 

  21. International Union against cancer (1982) TNM classification of malignant tumors, 3rd edn. Springer, Berlin Heidelberg New York

    Google Scholar 

  22. Lange PH, McIntire KR, Waldmann TA et al. (1976) Serum alpha-fetoprotein and human chorionic gonadotrophin in the diagnosis and management of non-seminomatous germ cell testicular cancer. N Engl J Med 295:1237–1240

    Article  PubMed  CAS  Google Scholar 

  23. Birch R, Williams S, Cone A et al. (1986) Prognostic factors for favorable outcome in disseminated germ cell tumors. J Clin Oncol 4:400–407

    PubMed  CAS  Google Scholar 

  24. Hricak H (1988) Detection and staging of renal neoplasms. Radiology 166:643–649

    PubMed  CAS  Google Scholar 

  25. Chisholm GD, Roy RR (1971) The systemic effect of malignant renal tumors. Br J Urol 43:687–693

    Article  PubMed  CAS  Google Scholar 

  26. National Institute of Health Consensus Conference (1987) The management of clinically localized prostate cancer. J Urol 138:1369–1375

    Google Scholar 

  27. Gleason DF (1977) The veterans administration cooperative urologic research group: histologic grading and clinical staging of prostatic carcinoma. In: Tannenbaumm M (ed) Urologie pathology: the prostate. Lea and Febiger, Philadelphia, pp 171–198

    Google Scholar 

  28. Paulson D, Piserchia PV, Gardner W (1980) Prediction of lymphatic spread in prostatic adenocarcinoma: uro-oncology research group study. J Urol 123:697–699

    PubMed  CAS  Google Scholar 

  29. Oesterling JE, Brendler CB, Epstein JL et al. (1987) Correlation of clinical stage, serum prostatic acid phosphatase, and preoperative Gleason grade with final pathologic stage in 275 patients with clinically localized adenocarcinoma of the prostate. J Urol 138:92–98

    PubMed  CAS  Google Scholar 

  30. Tinari N, Natoli C, Angelucci D et al. (1993) DNA and S-phase fraction analysis by flow cytometry in prostate cancer. Cancer 71:1289–1296

    Article  PubMed  CAS  Google Scholar 

  31. Walsh PC, Epstein JL, Lowe FC (1987) Potency following radical prostatectomy with wide unilateral excision of the neurovascular bundle. J Urol 138:823–827

    PubMed  CAS  Google Scholar 

  32. de Voogt HJ, Smith PH, Pavone-Macaluso M et al. (1986) Cardiovascular side effects of ethylstilbestrol, cyproterone acetate, medroxyprogesterone acetate and estramustrine phosphate used for the treatment of advanced prostatic cancer. J Urol 135:303–307

    PubMed  Google Scholar 

  33. Serially AV, Redding TW, Comaru-Schally AM (1983) Inhibition of prostate tumors by agonistic and antagonistic analogues of LH-RH. Prostate 4:545–552

    Article  Google Scholar 

  34. Bretton PR, Herr HW, Kimmel M et al. (1989) Flow cytometry as a predictor of response and progression in patients with superficial bladder cancer treated with bacillus Calmette-Guerìn. J Urol 141:1332–1336

    PubMed  CAS  Google Scholar 

  35. Slack NH, Prout GR Jr (1980) The heterogeneity of invasive bladder carcinoma and different response to treatment. J Urol 123:644–652

    PubMed  CAS  Google Scholar 

  36. Torti FM, Lum BL (1983) The biology and treatment of superficial bladder cancer. J Clin Oncol 2:505–531

    Google Scholar 

  37. Wijkstrom H, Granberg-Ohman I, Tribukait B (1984) Chromosomal and DNA pattern in transitional cell bladder carcinoma. Cancer 53:1718–1723

    Article  PubMed  CAS  Google Scholar 

  38. Prout GR Jr, Lin CW, Benson R Jr et al. (1987) Photodynamic therapy with hematoporphyrin derivative in the treatment of superficial transition-cell carcinoma of the bladder. N Engl J Med 317:1251–1255

    Article  PubMed  Google Scholar 

  39. Kalish LA, Garnick MB, Richie JP (1987) Appropriate endpoints for superficial bladder cancer clinical trials. J Clin Oncol 5:2004–2008

    PubMed  CAS  Google Scholar 

  40. Herr HW, Badalament RA, Amato DA et al. (1989) Superficial bladder cancer treated with bacillus Calmette-Guerìn. J Urol 141:22–29

    PubMed  CAS  Google Scholar 

  41. Raghavan D, Wallace DMA, Sandeman T et al. (1989) First randomized trial of pre-emptive intravenous cisplatin for invasive transitional cell carcinoma of the bladder. Proc Am Soc Clin Oncol 8:133 (abstract)

    Google Scholar 

  42. Khanderan JD, Esson PJ, Dewys WD et al. (1985) Comparative activity and toxicity of DDP and a combination of doxorubicin, cyclophosphamide and DDP in disseminated transitional cell carcinoma of the urinary tract. J Clin Oncol 3:539–545

    Google Scholar 

  43. Hillcoat BL, Raghavan D, Matthews J et al. (1989) A randomized trial of cisplatin or cisplatin plus methotrexate in advanced cancer of the urothelial tract. J Clin Oncol 7:706–709

    PubMed  CAS  Google Scholar 

  44. Vugrin D, Whitmore W, Cvitkovic E et al. (1981) Adjuvant chemotherapy with VAB-3 of stage II-B testicular cancer. Cancer 48:233–237

    Article  PubMed  CAS  Google Scholar 

  45. Williams SD, Birch R, Einhorn LH et al. (1987) Treatment of disseminated germ cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide. N Engl J Med 316:1435–1440

    Article  PubMed  CAS  Google Scholar 

  46. Bredael JJ, Vugrin D, Whitmore WF et al. (1983) Selective experience with surgery and combination chemotherapy in the treatment of nonseminomatous testis tumors. J Urol 129:985–988

    PubMed  CAS  Google Scholar 

  47. Williams SD, Stablein DM, Einhorn LH et al. (1987) Immediate adjuvant chemotherapy versus observation with treatment at relapse in pathological stage II testicular cancer. N Engl J Med 317:1433–1438

    Article  PubMed  CAS  Google Scholar 

  48. Skinner DG, Colvin RB, Vermillon CD et al. (1971) Diagnosis and management of renal cell carcinoma. Cancer 28:1165–1174

    Article  PubMed  CAS  Google Scholar 

  49. Waxman J, Thomas H (1990) Is the outlook changing for patients with renal cell carcinoma? Eur J Cancer 26:860–862

    Article  PubMed  CAS  Google Scholar 

  50. Lynch HT, Ens JA, Lynch JF et al. (1990) The Lynch syndrome II and urological malignancies. J Urol 143:24–28

    PubMed  CAS  Google Scholar 

  51. Lynch HT, Richardson JD, Mohammad Amin MD et al. (1991) Variable gastrointestinal and urologic cancers in a Lynch syndrome II kindred. Dis Colon Rectum 34:891–895

    Article  PubMed  CAS  Google Scholar 

  52. Cannon-Albright L, Bishop TD, Skolnick M et al. (1982) Genetic epidemiology of prostate cancer in the Utah Mormon genealogy. Cancer Surv 1:47–69

    Google Scholar 

  53. Spitz MR, Currier RD, Fueger JJ et al. (1991) Familial pattern of prostate cancer. J Urol 146:1305–1307

    PubMed  CAS  Google Scholar 

  54. Steinberg GD, Carter BS, Beaty Th et al. (1990) Family history of the risk of prostate cancer. Prostate 17:337–347

    Article  PubMed  CAS  Google Scholar 

  55. Carter BS, Carter HB, Isaacs JT (1990) Epidemiologic evidence regarding predisposing factors to prostate cancer. Prostate 16:187–197

    Article  PubMed  CAS  Google Scholar 

  56. Carter BS, Beaty TH, Steinberg GD et al. (1992) Mendelian inheritance of familial prostate cancer. Proc Natl Acad Sci USA 89:3367–3371

    Article  PubMed  CAS  Google Scholar 

  57. Fraumeni JF Jr, Thomas LB (1967) Malignant bladder tumors in a man and his three sons. JAMA 201:507–509

    Article  Google Scholar 

  58. McCullough DL, Lamm DL, McLaughlin AP III et al. (1975) Familial transitional cell carcinoma of the bladder. J Urol 113:629–633

    PubMed  CAS  Google Scholar 

  59. Lynch HT, Walzak MP, Fried R et al. (1979) Familial factors in bladder carcinoma. J Urol 122:458–461

    PubMed  CAS  Google Scholar 

  60. Najem GR, Louria DB, Seebode JJ et al. (1982) Lifetime occupation, smoking, caffeine, saccharine, hair dyes and bladder carcinogenesis. Int J Epidemiol 11:212–217

    Article  PubMed  CAS  Google Scholar 

  61. Petrova-Bocharova T, Chernozemsky IN, Nikolov IG et al. (1977) Families with multiple cases of urinary system tumors. JNCI 59:1419–1421

    Google Scholar 

  62. Marchetto D, Li FP, Henson DE (1983) Familial carcinoma of ureters and other genitourinary organs. J Urol 130:772–773

    PubMed  CAS  Google Scholar 

  63. Burland CE, Juzek RH (1966) Familial occurrence of carcinoma of the ureter. J Urol 96:697–700

    Google Scholar 

  64. Cartwright RA (1979) Genetic association with bladder cancer. Br Med J 2:798

    Article  PubMed  CAS  Google Scholar 

  65. Kantor AF, Hartge P, Hoover RN et al. (1985) Familial and environmental interactions in bladder cancer risk. Int J Cancer 35:703–706

    Article  PubMed  CAS  Google Scholar 

  66. Sellers TA, Kushi LH, Potter JD et al. (1992) Effect of family history, body-fat distribution, and reproductive factors on the risk of post-menopausal breast cancer. N Engl J Med 326:1323–1329

    Article  PubMed  CAS  Google Scholar 

  67. Dieckmann KP, Boeckmann W, Brosig W et al. (1986) Bilateral testicular germ cell tumors. Report of nine cases and review of the literature. Cancer 57:1254–1259

    Article  PubMed  CAS  Google Scholar 

  68. Dieckmann KP, Becker T, Jonas D et al. (1987) Inheritance of testicular cancer. Arguments based on a report of 3 cases and review of the literature. Oncology 44:367–373

    Article  PubMed  CAS  Google Scholar 

  69. Weissbach L, Widmann T (1986) Familial tumor of the testis. Eur Urol 12:104–109

    PubMed  CAS  Google Scholar 

  70. Patel SR, Kvols LK, Richardson RL (1990) Familial testicular cancer: report of 6 cases and review of the literature. Mayo Clin Proc 65:585–591

    Google Scholar 

  71. Goss PE, Bulbul MA (1990) Familial testicular cancer in 5 members of a cancer-prone kindred. Cancer 66:2044–2049

    Article  PubMed  CAS  Google Scholar 

  72. Gedde Dahl T, Hannisdal E, Klepp OH et al. (1985) Testicular neoplasms occurring in 4 brothers: a search for a genetic predisposition. Cancer 55:2005–2011

    Article  Google Scholar 

  73. Tollerud DJ, Blattner WA, Fraser MC et al. (1985) Familial testicular cancer and urogenital developmental anomalies. Cancer 55:1849–1856

    Article  PubMed  CAS  Google Scholar 

  74. Forman D, Oliver RTD, Brett AR et al. (1992) Familial testicular cancer: a report of the U.K. family register, estimation of risk and HLA class 1 sib-pair analysis. Br J Cancer 65:255–262

    Article  PubMed  CAS  Google Scholar 

  75. Hartley AL, Birch JM, Kelsey AM et al. (1989) Are germ cell tumors part of the Li-Fraumeni cancer family syndrome? Cancer Genet Cytogenet 42:221–226

    Article  PubMed  CAS  Google Scholar 

  76. Franksson C, Bergstrand A, Ljundhal I et al. (1972) Renal carcinoma occurring in 5 siblings. J Urol 108:58–61

    PubMed  CAS  Google Scholar 

  77. Guirguis AB (1973) Renal-cell carcinoma: unusual occurrence in four members of one family. Urology 2:283–285

    Article  PubMed  CAS  Google Scholar 

  78. Cohen AJ, Li FP, Berg S et al. (1979) Hereditary renal-cell carcinoma associated with a chromosomal translocation. N Engl J Med 301:592–595

    Article  PubMed  CAS  Google Scholar 

  79. Arps S, Rodewald A, Schmalenberger B et al. (1993) Cytogenetic survey of 32 cancers of the prostate. Cancer Genet Cytogenet 66:93–99

    Article  PubMed  CAS  Google Scholar 

  80. Peehl DM (1993) Oncogenes in prostate cancer: an update. Cancer 71:1159–1164

    Article  PubMed  CAS  Google Scholar 

  81. Carter BS, Ewing CM, Ward WS et al. (1990) Allelic loss of chromosome 16q and lOq in human prostate cancer. Proc Natl Acad Sci USA 87:8751–8755

    Article  PubMed  CAS  Google Scholar 

  82. Isaacs WB, Carter BS, Ewing CM (1991) Wild-type p53 suppresses growth of human prostate cancer cells containing mutant p53 alleles. Cancer Res 51: 4716–4720

    PubMed  CAS  Google Scholar 

  83. Bookstein R, MacGrogan D, Hilsenbeck SG et al. (1993) p53 is mutated in a subset of advanced-stage prostate cancers. Cancer Res 53:3369–3373

    PubMed  CAS  Google Scholar 

  84. Gao X, Honn KV, Grignon D et al. (1993) Frequent loss of expression and LOH of the putative tumor suppressor gene DCC in prostatic carcinoma. Cancer Res 53:2723–2727

    PubMed  CAS  Google Scholar 

  85. Bova GS, Carter BS, Bussemakers MJG et al. (1993) Homozygous deletion and frequent allelic loss of chromosome 8p22 loci in human prostate cancer. Cancer Res 53:3869–3873

    PubMed  CAS  Google Scholar 

  86. Gibas Z, Prout GR, Pontes JE et al. (1986) A possible specific chromosomal change in transitional cell carcinoma of the bladder. Cancer Genet Cytogenet 19:229–238

    Article  PubMed  CAS  Google Scholar 

  87. Smeets W, Pauwels R, Laarakkers L et al. (1987) Chromosomal analysis of bladder cancer. Cancer Genet Cytogenet 29:29–41

    Article  PubMed  CAS  Google Scholar 

  88. Babu VR, Lutz M, Miles BJ et al. (1987) Tumor behavior in transitional cell carcinoma of the bladder in relation to chromosomal markers and histo-pathology. Cancer Res 47:6800–6805

    PubMed  CAS  Google Scholar 

  89. Fujita J, Srivastava SK, Kraus M et al. (1985) Frequency of molecular alterations affecting ras protooncogene in human urinary tract tumors. Proc Natl Acad Sci USA 82:3849–3853

    Article  PubMed  CAS  Google Scholar 

  90. Meyers FJ, Gumerlock PH, Kokoris SP et al. (1989) Human bladder and colon carcinomas contain activated ras p21. Cancer 63:2177–2181

    Article  PubMed  CAS  Google Scholar 

  91. Neal DE, Marsh C, Bennet MK (1985) Epidermal growth factor receptors in human bladder cancer. Lancet 1:366–368

    Article  PubMed  CAS  Google Scholar 

  92. Berger MS, Greefielg G, Gullick WJ et al. (1987) Evaluation of epidermal growth factor receptors in human bladder tumours. Br J Cancer 56:533–537

    Article  PubMed  CAS  Google Scholar 

  93. Reddy EP, Reynolds RK, Santos E et al. (1982) A point mutation is responsible for the acquisition of transforming properties by the T24 human bladder carcinoma oncogene. Nature 300:149–152

    Article  PubMed  CAS  Google Scholar 

  94. Fearon ER, Feinberg AP, Hamilton SH et al. (1985) Loss of genes on the short arm of chromosome 11 in bladder cancer. Nature 318:377–380

    Article  PubMed  CAS  Google Scholar 

  95. Olumi AF, Tsay YC, Jones P et al. (1990) Allelic loss of chromosome 17p distinguishes high grade from low grade transitional cell carcinoma of the bladder. Cancer Res 50:7081–7083

    PubMed  CAS  Google Scholar 

  96. Cairns P, Shaw ME, Knowles MA (1993) Initiation of bladder cancer may involve deletion of a tumour suppressor gene on chromosome 9. Oncogene 8:1083–1085

    PubMed  CAS  Google Scholar 

  97. Miyao N, Tsai YC, Lerner SP et al. (1993) Role of chromosome 9 in human bladder cancer. Cancer Res 53:4066–4070

    PubMed  CAS  Google Scholar 

  98. Sidranski D, von Eschenbach A, Tsay YC et al. (1991) Identification of p53 mutations in bladder cancers and urine samples. Science 252:706–709

    Article  Google Scholar 

  99. Lipponen PK (1993) Overexpression of p53 in transitional bladder cancer and its prognostic value. Int J Cancer 53:365–370

    Article  PubMed  CAS  Google Scholar 

  100. Fujimoto K, Yamada Y, Okajima E et al. (1992) Frequent association of p53 gene mutation in invasive bladder cancer. Cancer Res 52:1393–1398

    PubMed  CAS  Google Scholar 

  101. Logothetis CJ, Xu HJ, Ro JY et al. (1992) Altered expression of retinoblastoma protein and known prognostic variables in locally advanced bladder cancer. JNCI 84:1256–1261

    PubMed  CAS  Google Scholar 

  102. Bàrtkovà J, Bàrtek J, Lukàs J et al. (1991) p53 protein alterations in human testicular cancer including pre-invasive intratubular germ-cell neoplasia. Int J Cancer 49:196–202

    Article  PubMed  Google Scholar 

  103. Baker SJ, Fearon AR, Nigro JM et al. (1989) Chromosome 17 deletions and p53 mutations in colorectal carcinomas. Science 244:217–221

    Article  PubMed  CAS  Google Scholar 

  104. Baker SJ, Preisinger AC, Jessup JM et al. (1990) p53 mutations occur in combination with 17p allelic deletions as late events in colorectal tumorigenesis. Cancer Res 50:7717–7722

    PubMed  CAS  Google Scholar 

  105. Heimdal K, Lothe RA, Lystad S et al. (1993) No germline p53 mutations detected in familial and bilateral testicular cancer. Genes Chromos Cancer 6:92–97

    Article  PubMed  CAS  Google Scholar 

  106. Pathak S, Strong LC, Ferrell RE et al. (1982) Familial renal cell carcinoma with a 3; 11 chromosome translocation limited to tumor cells. Science 217:939–940

    Article  PubMed  CAS  Google Scholar 

  107. Wang N, Perkins KL (1984) Involvement of band 3pl4 in t(3;8) hereditary renal carcinoma. Cancer Genet Cytogenet 11:479–481

    Article  PubMed  CAS  Google Scholar 

  108. Zbar B, Brauch H, Talmadge C et al. (1987) Loss of alleles of loci on the short arm of chromosome 3 in renal cell carcinoma. Nature 327:721–724

    Article  PubMed  CAS  Google Scholar 

  109. LaForgia S, Lasota J, Latif F et al. (1993) Detailed genetic and physical map of the 3p chromosome region surrounding the familial renal cell carcinoma chromosome translocation, t(3;8) (pl4.2;q24.1). Cancer Res 53:3118–3124

    Google Scholar 

  110. Yamakawa K, Morita R, Takahashi E et al. (1991) A detailed deletion mapping of the short arm of chromosome 3 in sporadic renal cell carcinoma. Cancer Res 51:4707–4711

    PubMed  CAS  Google Scholar 

  111. Morita R, Ishikawa J, Tsutsumi M et al. (1991) Allelotype of renal cell carcinoma. Cancer Res 51:820–823

    PubMed  CAS  Google Scholar 

  112. Reiter RE, Anglard P, Liu S et al. (1993) Chromosome 17p deletions and p53 mutations in renal cell carcinoma. Cancer Res 53:3092–3097

    PubMed  CAS  Google Scholar 

  113. Morita R, Saito S, Ishikawa J et al. (1991) Common regions of deletion on chromosomes 5q, 6q and lOq in renal cell carcinoma. Cancer Res 51:5817–5820

    PubMed  CAS  Google Scholar 

  114. Kovacs G, Szucs S, DeRiese W et al. (1987) Specific chromosome aberration in human renal cell carcinoma. Cancer Res 40:171–178

    CAS  Google Scholar 

  115. Presti JC, Rao P, Chen Q et al. (1991) Histopathological, cytogenetic, and molecular characterization of renal cortical tumors. Cancer Res 51:1544–1552

    PubMed  Google Scholar 

  116. Tory K, Brauch H, Lineham M et al. (1989) Specific genetic change in tumors associated with von Hippel-Lindau disease. JNCI 1097–1101

    Google Scholar 

  117. Latif F, Tory K, Gnarra J et al. (1993) Identification of the von Hippel-Lindau disease tumor suppressor gene. Science 270:1317–1320

    Article  Google Scholar 

  118. Naylor SL, Johnson BE, Minna JD et al. (1987) Loss of heterozygosity of chromosome 3p markers in small-cell lung cancer. Nature 329:451–454

    Article  PubMed  CAS  Google Scholar 

  119. Yokota J, Tsukada Y, Nakajima et al. (1989) Loss of heterozygosity on the short arm of chromosome 3 in carcinoma of the uterine cervix. Cancer Res 49:3598–3601

    PubMed  CAS  Google Scholar 

  120. Mori N, Yokota J, Oshimura M et al. (1989) Concordant deletions of chromosome 3p and loss of heterozygosity for chromosome 13 and 17 in small cell lung carcinoma. Cancer Res 49:5130–5135

    PubMed  CAS  Google Scholar 

  121. Decker HJH, Wullich B, Whaley JM et al. (1992) Cytogenetic and molecular studies of a familial renal cell carcinoma. Cancer Genet Cytogenet 63:25–31

    Article  PubMed  CAS  Google Scholar 

  122. Walker C, Goldsworthy TL, Wolf DC et al. (1992) Predisposition to renal cell carcinoma due to alteration of a cancer susceptibility gene. Science 255:1693–1695

    Article  PubMed  CAS  Google Scholar 

  123. Funaki K, Evnritt J, Oshimura M et al. (1991) Hereditary renal cell carcinoma in the rat associated with nonrandom loss of chromosomes 5 and 6. Cancer Res 51:4415–4422

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Istituto di Patologia Medica Policlinico, Università degli Studi di Modena, Via del Pozzo, 71, 41100, Modena, Italy

    Prof. Dr. M. Ponz de Leon

Authors
  1. Prof. Dr. M. Ponz de Leon
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 1994 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

de Leon, M.P. (1994). Familial Factors in Cancer of the Genitourinary Tract. In: Familial and Hereditary Tumors. Recent Results in Cancer Research, vol 136. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-85076-9_20

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-85076-9_20

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-85078-3

  • Online ISBN: 978-3-642-85076-9

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation